Convert Pharmaceuticals' Series A Round

Convert Pharmaceuticals raised a round of funding on February 28, 2018.

Convert Pharmaceuticals develops prodrugs that are inert upon administration to patients, but transform into potent anti-cancer agents upon entering tumors. Convert's proprietary insights in both the …

Articles about Convert Pharmaceuticals' Series A Round: